Evaluation of Potential Drug Side Effects in Multidrug-Resistant Tuberculosis Patients who have been Diagnosed by Genexpert Method
Objective: to evaluation potential drug side effects in multidrug-resistant tuberculosis patients who have been diagnosed by genexpert method
Design: this research used a descriptive analysis research design. The population used in this study were MDR-TB patients at the DOTS TB and MDR TB Poly in RSUP Haji Adam Malik Medan in 2017-2019, the research sample obtained was 100 patients and data collection used a cross sectional approach.
Interventions: the intervened variable were therapeutic regimen, used of additional drugs and duration of therapy
Main outcome measures: the main measurement in this study was therapeutic side effects
Results: the results showed that treatment of MDR-TB patients mostly used the standard combination regimen, namely Km-Lfx-Eto-Cs-Z- (H) - (E) as much as 35%. Side effect found was nausea at 20.55%. The use of additional vitamin B6 drugs in MDR-TB patients was 92% because treatment using kanamycin, etionamide, levofloxacin and cycloserine had side effects of peripheral neuropathy. Of the length of treatment that was still undergoing treatment in 2019, the highest number was 59%.
Conclusion: it could be concluded the most common side effect found in the average number was nausea at 20.55% and peripheral neuropathy.
2. Nawas, A. Penatalaksanaan TB –MDR Dan Strategi DOTS Plus. Jurnal Tuberkulosis Indonesia. 2010; 7:231
3. Nofryanda, Dr. Analisi molekuler pada proses resistensi mikobakterium tuberculosis terhadap obat – obat anti tuberculosis. Skripsi, Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Keedokteran Universitas Andalas Padang. 2010; 21-32.
4. Dasopang, E.S., Hasanah, F., & Nisak, C. Analisis Deskriptif Efek Samping Penggunaan Obat Anti Tuberculosis pada Pasien TBC di RSUD. Pirngadi Medan, Jurnal Penelitian Farmasi Herbal. 2019; 2:47.
5. Sugiyono. Metodologi Penelitian Kuantitatif Kualitatif. Bandung : Alfabeta. 2011. p. 31.
6. Notoatmodjo., 2012. Metode Penelitian Kesehatan. Jakarta: Rineka Cipta. 2012. p. 42.
7. Kemenkes RI. Tuberkulosis Temukan Obati Sampai Sembuh. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI. 2018. p. 5.
8. Kemenkes RI. Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resisten Obat. Jakarta : Kementerian Kesehatan RI. 2018. p.34
9. Dani, Rosdiana. Tuberkulosis Paru Resisten Obat dengan Komorbiditas Diabetes Mellitus. Jurnal Kesehatan Melayu 2017. 2017; 45-51.
10. Dasopang, E.S., Harahap, U., & Lindarto, D., 2015. Polifarmasi dan Interaksi Obat Pasien Usia Lanjut Rawat Jalan dengan Penyakit Metabolik, Jurnal Farmasi Klinis Indonesia. 2015; 4:236-237.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).